952 related articles for article (PubMed ID: 30794926)
21. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
[TBL] [Abstract][Full Text] [Related]
22. Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1).
Dwivedi Y; Rizavi HS; Zhang H; Roberts RC; Conley RR; Pandey GN
Int J Neuropsychopharmacol; 2009 Nov; 12(10):1337-54. PubMed ID: 19835659
[TBL] [Abstract][Full Text] [Related]
23. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
24. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
Mandal R; Becker S; Strebhardt K
Oncogene; 2016 May; 35(20):2547-61. PubMed ID: 26364606
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
[TBL] [Abstract][Full Text] [Related]
26. Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer.
Salh B; Marotta A; Matthewson C; Ahluwalia M; Flint J; Owen D; Pelech S
Anticancer Res; 1999; 19(1B):731-40. PubMed ID: 10216485
[TBL] [Abstract][Full Text] [Related]
27. MEK1 and the extracellular signal-regulated kinases are required for the stimulation of IL-2 gene transcription in T cells.
Whitehurst CE; Geppert TD
J Immunol; 1996 Feb; 156(3):1020-9. PubMed ID: 8557975
[TBL] [Abstract][Full Text] [Related]
28. Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants.
Brognard J; Dennis PA
Cell Death Differ; 2002 Sep; 9(9):893-904. PubMed ID: 12181740
[TBL] [Abstract][Full Text] [Related]
29. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK.
Brennan DF; Dar AC; Hertz NT; Chao WC; Burlingame AL; Shokat KM; Barford D
Nature; 2011 Apr; 472(7343):366-9. PubMed ID: 21441910
[TBL] [Abstract][Full Text] [Related]
30. PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway.
Coles LC; Shaw PE
Oncogene; 2002 Mar; 21(14):2236-44. PubMed ID: 11948406
[TBL] [Abstract][Full Text] [Related]
31. Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.
Little AS; Balmanno K; Sale MJ; Smith PD; Cook SJ
Biochem Soc Trans; 2012 Feb; 40(1):73-8. PubMed ID: 22260668
[TBL] [Abstract][Full Text] [Related]
32. Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes.
Adams DG; Coffee RL; Zhang H; Pelech S; Strack S; Wadzinski BE
J Biol Chem; 2005 Dec; 280(52):42644-54. PubMed ID: 16239230
[TBL] [Abstract][Full Text] [Related]
33. The 96 kDa protein kinase activated by oncogenic Ras in Xenopus egg extracts is also activated by constitutively active Mek: activation requires serine/threonine phosphorylation.
Pan BT; Zhang Y; Brott B; Chen DH
Oncogene; 1997 Apr; 14(14):1653-60. PubMed ID: 9135066
[TBL] [Abstract][Full Text] [Related]
34. Flagellin and lipopolysaccharide stimulate the MEK-ERK signaling pathway in chicken heterophils through differential activation of the small GTPases, Ras and Rap1.
Kogut MH; Genovese KJ; He H
Mol Immunol; 2007 Mar; 44(7):1729-36. PubMed ID: 17045653
[TBL] [Abstract][Full Text] [Related]
35. RAF protein-serine/threonine kinases: structure and regulation.
Roskoski R
Biochem Biophys Res Commun; 2010 Aug; 399(3):313-7. PubMed ID: 20674547
[TBL] [Abstract][Full Text] [Related]
36. Opposite long-term regulation of c-Myc and p27Kip1 through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells.
Lefevre G; Calipel A; Mouriaux F; Hecquet C; Malecaze F; Mascarelli F
Oncogene; 2003 Dec; 22(55):8813-22. PubMed ID: 14654778
[TBL] [Abstract][Full Text] [Related]
37. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
[TBL] [Abstract][Full Text] [Related]
38. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade.
Lengyel E; Wang H; Gum R; Simon C; Wang Y; Boyd D
Oncogene; 1997 May; 14(21):2563-73. PubMed ID: 9191056
[TBL] [Abstract][Full Text] [Related]
39. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors.
Jameson KL; Mazur PK; Zehnder AM; Zhang J; Zarnegar B; Sage J; Khavari PA
Nat Med; 2013 May; 19(5):626-630. PubMed ID: 23603816
[TBL] [Abstract][Full Text] [Related]
40. Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation.
Marampon F; Ciccarelli C; Zani BM
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
